CMS shares Medicare Administrative Contractor (MAC) update regarding proposed Local Coverage Determination (LCD) for MolDx Molecular Testing for Solid Organ Allograft Rejection

Aug. 26, 2024
CMS update.

In response to public comments and upon further review of evidence, Medicare Administrative Contractors (MACs) are not finalizing the most recently proposed Local Coverage Determination (LCD) for MolDx Molecular Testing for Solid Organ Allograft Rejection, which is a blood test that monitors for organ transplantation rejection, and instead anticipate issuing a new proposed LCD in the coming months. The Centers for Medicare and Medicaid Cervices (CMS) informed partners of this update.

Patients with transplanted hearts, lungs, or kidneys who meet Medicare’s existing local coverage criteria can continue to access these blood tests under the current LCD.

CMS release

ID 109697152 © Leigh_341 | Dreamstime.com
dreamstime_xxl_109697152
JLco - Julia Amaral / iStock / Getty Images Plus / Getty Images
untitled_design_11
ID 167606759 © Pop Nukoonrat | Dreamstime.com
dreamstime_xxl_167606759
ID 252304527 © Yanadee | Dreamstime.com
dreamstime_xxl_252304527